PMID- 36790032
OWN - NLM
STAT- MEDLINE
DCOM- 20230510
LR  - 20230511
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 8
DP  - 2023 Apr
TI  - Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in 
      patients with hepatocellular carcinoma: A real-world cohort study.
PG  - 9202-9212
LID - 10.1002/cam4.5661 [doi]
AB  - OBJECTIVE: Lenvatinib plus anti-programmed death-1 (anti-PD-1) antibody 
      combinations have shown potent anti-tumor effect in phase I/II trials in advanced 
      or unresectable hepatocellular carcinoma (HCC), but real-world data are limited. 
      METHODS: To investigate the effectiveness and safety of lenvatinib plus anti-PD-1 
      antibodies in a real-world cohort, we retrospectively evaluated 210 patients with 
      unresectable or advanced HCC treated with these regimens between October 2018 and 
      February 2022. RESULTS: The objective response rate and disease control rate per 
      Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 were 28.1% and 75.2%. 
      Median overall survival (OS) and progression-free survival (PFS) in the overall 
      cohort were 17.2 and 8.4 months, respectively. Median OS and PFS of patients 
      receiving first-line treatment reached 18.9 and 9.6 months. Median OS was 
      significantly longer in patients with Child-Pugh class A versus B (18.8 vs. 
      5.9 months, respectively), as was median PFS (9.1 vs. 4.4 months). Patients with 
      albumin-bilirubin (ALBI) grade 1 versus grade 2/3 also had significantly greater 
      median OS (23.5 vs. 13.4 months). Treatment-related adverse events (AEs) occurred 
      in 79.5% of patients. Patients with ALBI grade 2/3 had a higher rate of grade 3/4 
      AEs than patients with ALBI grade 1 (57.5% vs. 38.5%). CONCLUSION: Lenvatinib 
      combined with anti-PD-1 antibody therapy was effective in patients with 
      sufficient liver function reserve. Further study is needed to improve therapeutic 
      efficacy and AE management in patients with Child-Pugh class B or ALBI grade 2/3.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Xu, Ming-Hao
AU  - Xu MH
AUID- ORCID: 0000-0001-5656-8090
AD  - Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Huang, Cheng
AU  - Huang C
AD  - Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Li, Mei-Ling
AU  - Li ML
AD  - Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Zhu, Xiao-Dong
AU  - Zhu XD
AD  - Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Tan, Chang-Jun
AU  - Tan CJ
AD  - Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Zhou, Jian
AU  - Zhou J
AUID- ORCID: 0000-0002-2118-1117
AD  - Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Fan, Jia
AU  - Fan J
AUID- ORCID: 0000-0001-5158-629X
AD  - Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Sun, Hui-Chuan
AU  - Sun HC
AUID- ORCID: 0000-0003-3761-7058
AD  - Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Shen, Ying-Hao
AU  - Shen YH
AUID- ORCID: 0000-0001-6476-0648
AD  - Department of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230215
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - EE083865G2 (lenvatinib)
RN  - 0 (Albumins)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Cohort Studies
MH  - Retrospective Studies
MH  - *Liver Neoplasms/drug therapy
MH  - Albumins
MH  - Bilirubin
PMC - PMC10166966
OTO - NOTNLM
OT  - ALBI grade
OT  - Child-Pugh class
OT  - anti-PD-1 antibody
OT  - hepatocellular carcinoma
OT  - lenvatinib
COIS- No conflicts of interest were declared.
EDAT- 2023/02/16 06:00
MHDA- 2023/05/10 06:42
PMCR- 2023/02/15
CRDT- 2023/02/15 07:22
PHST- 2022/11/24 00:00 [revised]
PHST- 2022/08/02 00:00 [received]
PHST- 2023/01/17 00:00 [accepted]
PHST- 2023/05/10 06:42 [medline]
PHST- 2023/02/16 06:00 [pubmed]
PHST- 2023/02/15 07:22 [entrez]
PHST- 2023/02/15 00:00 [pmc-release]
AID - CAM45661 [pii]
AID - 10.1002/cam4.5661 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Apr;12(8):9202-9212. doi: 10.1002/cam4.5661. Epub 2023 Feb 15.